During a live event, Robert Orlowski, MD, PhD, and participants discussed selinexor combinations, dosing, and nausea prevention for an older patient with late relapsed multiple myeloma who declines CAR T.
ESMO data show the phase 3 INTerpath-001 trial of intismeran autogene plus pembrolizumab improved recurrence-free survival in resected stage IIB to IV melanoma.
During a live event, Amy Cummings, MD, discussed a patient case of a 69-year-old man with non–small cell lung cancer and an HER2 exon 20 insertion mutation.